Impact of Brokerage Rating on BioScrip, Inc.(BIOS)

Many BioScrip, Inc.(BIOS) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. BioScrip Inc was Initiated by Lake Street on Jan 3, 2017 to Buy, Price Target of the shares are set at $4.50.

Company has reported several Insider transactions to the SEC, on Nov 14, 2016, Jeffrey M Kreger (CFO) purchased 10,000 shares at 1.32 per share price.On Nov 14, 2016, Daniel E Greenleaf (CEO) purchased 16,000 shares at 1.30 per share price.On Nov 14, 2016, R Carter Pate (director) purchased 20,000 shares at 1.30 per share price.

BioScrip Inc Last issued its quarterly earnings results on Nov 7, 2016. The company reported $-0.12 EPS for the quarter, missing the analyst consensus estimate by $ -0.07. Analyst had a consensus of $-0.05. The company had revenue of $224.50 million for the quarter, compared to analysts expectations of $223.28 million. The companys revenue was down -9.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.38 EPS.

BioScrip, Inc. (NASDAQ:BIOS) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.5 by 4 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 1 Brokerage Firms have advised hold.

BioScrip, Inc. (NASDAQ:BIOS): The mean estimate for the short term price target for BioScrip, Inc. (NASDAQ:BIOS) stands at $2.19 according to 4 Analysts. The higher price target estimate for the stock has been calculated at $3 while the lower price target estimate is at $2.

BioScrip, Inc. (NASDAQ:BIOS) rose 2.48% or 0.04 points on Tuesday and made its way into the gainers of the day. After trading began at $1.6 the stock was seen hitting $1.65 as a peak level and $1.58 as the lowest level. The stock ended up at $1.65. The daily volume was measured at 1,763,745 shares. The 52-week high of the share price is $3.43 and the 52-week low is $0.98. The company has a market cap of $194 million.

BioScrip provides comprehensive pharmaceutical care solutions. We partner with healthcare payors, pharmaceutical manufacturers, government agencies, physicians, and patients to deliver cost effective programs that enhance the quality of patient life. We focus our products and services in two core areas: specialty medication distribution and clinical management services, both nationally and community-based and pharmacy benefit management services.


For any feedback and suggestions contact author at

Add Comment